Home Blog Page 1387

Angela Zhao Named CEO of GLP China

  • GLP appoints its China head of logistics and industrial real estate to lead integrated business spanning logistics, digital infrastructure and new energy, and fund management
  • The newly created China CEO role will report to Ming Mei, who continues as Global CEO
  • Teresa Zhuge, immediate past Executive Vice Chairwoman of GLP China, moves into expanded global leadership role while remaining on GLP China Board of Directors

SINGAPORE, Jan. 14, 2026 /PRNewswire/ — GLP Pte Ltd (“GLP” and with its subsidiaries the “Group”) today announced the appointment of Angela Zhao as CEO of GLP China. The appointment forms part of GLP’s long-term succession planning and reflects its strategy to further strengthen integration and synergies across its new-economy platforms in China.

Angela Zhao, CEO, GLP China
Angela Zhao, CEO, GLP China

Angela is a founding member and seasoned GLP executive. Since joining in 2003, she has served in key leadership positions, earning a reputation for operational excellence and data-driven strategies. Between 2018 and 2025, Angela held the position of Co-President, China Logistics and Industrial Real Estate, where she led the strategy, investment and operations of an approximately 50 million square metres portfolio spanning across 70 cities and municipalities, while incubating new growth engines such as intelligent industrial parks.

“Angela has been part of GLP from the very beginning and has played an instrumental role in shaping the growth and evolution of our China business,” said Ming Mei, CEO of GLP. “She combines deep operating experience with a strong sense of ownership and care for the business. I have full confidence in her ability to lead our China platform with rigor, ambition and the entrepreneurial spirit that defines GLP.”

“I am honored and excited to take on this next chapter after more than 20 years of growing with GLP,” said Angela Zhao, CEO of GLP China. “Over the years, we have built something truly special — a highly integrated and differentiated new-economy platform, driven by exceptional people, strong execution and a deep understanding of our customers. I look forward to continuing to work closely with our teams to capture new opportunities and deliver sustainable, performance-led growth.”

Angela will report directly to Ming Mei, who continues in his role as Global CEO, and is supported by a seasoned China management team, ensuring continuity and driving future success.

Teresa Zhuge, immediate past Executive Vice Chairwoman of GLP China, continues as a member of GLP’s Global Executive Committee and GLP China Board of Directors. In her newly expanded global role, she will assume broader firm-wide management, strategy and decision-making responsibilities at the GLP Group level.

“I am excited to step into this broader global role and look forward to contributing in an expanded capacity, supporting the continued success of both our China and global platforms,” said Teresa Zhuge, Global Executive Committee Member of GLP.

GLP China is a leading new-economy infrastructure investment manager with integrated capabilities in asset development and operations. Building on its long heritage in logistics, the platform has expanded into highly synergistic sectors, including hyperscale digital infrastructure supported by its new energy platform, creating a scaled and integrated ecosystem to serve China’s evolving economy.

About Angela Zhao

Angela Zhao is Chief Executive Officer of GLP China. She leads the Group’s Greater China business across logistics, digital infrastructure and new energy, and fund management. 

Angela has over two decades of strategy, investment and operations experience in real estate and infrastructure. A founding member of the China platform, Angela has been instrumental in shaping the company’s growth for over 20 years and building up a brand synonymous with the gold standard for warehousing solutions and supply chain competitiveness.

In 2011, Angela spearheaded GLP’s entry into the business park sector, introducing intelligent industrial parks to capitalize on emerging demand from R&D and high-tech companies. This generated a new engine of growth and deepened GLP’s leadership in new economy sectors. In her various leadership capacities, Angela champions the use of smart technologies and data analytics to drive performance driven growth and business transformation.

Prior to joining GLP in 2003, Angela developed her career at Ascendas Group where she was responsible for business development in China.

Angela holds an MBA from the MIT Sloan School of Management/Fudan University and received her Bachelor’s degree in Engineering from Shanghai University.

About GLP China

GLP China is a new economy infrastructure investment manager with integrated capabilities in asset development and operations. Its market-leading logistics and industrial portfolio comprises 50 million sqm of total space under management, including approximately 40 million sqm in operation across 70 cities, serving over 2,500 domestic consumption focused customers. GLP also ranks among China’s top data center operators with 1.4 GW of secured IT capacity and approximately 1 GW of renewable capacity under management. To learn more about GLP China, visit www.glp.com.cn.

About GLP

GLP is a leading global investor, thematic business builder and investment manager, focused on creating scaled platforms within its core sectors of logistics, digital infrastructure and renewable energy. The Group, through its asset management arm GLP Capital Partners, manages approximately US$80 billion of assets under management and has a proven track record of incubating and scaling platforms across markets and strategies through development, strategic M&A and partnerships. To learn more about GLP, visit www.glp.com/global.

This press release is not an offer of securities for sale or a solicitation of an offer to purchase securities. The information in this press release may not contain, and you may not rely on this press release as providing, all material information concerning the condition (financial or other), earnings, business affairs, business prospects, properties or results of operations of GLP or its subsidiaries. This release may contain forward-looking statements that involve risks and uncertainties. Forward-looking statements include statements regarding the intent, belief and current expectations of GLP or its officers with respect to various matters. When used in this press release, the words “expects,” “believes,” “anticipates,” “plans,” “may,” “will,” “should,” “intends,””foresees” “estimates,” “projects,” and similar expressions, and the negatives thereof, are intended to identify forward-looking statements. Similarly, statements that describe objectives, plans or goals also are forward-looking statements. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. Representative examples of these factors include (without limitation) general industry and economic conditions, interest rate trends, cost of capital and capital availability, availability of real estate properties, competition from other companies and venues for the sale/distribution of goods and services, shifts in customer demands, customers and partners, changes in operating expenses, including employee wages, benefits and training, governmental and public policy changes, and the continued availability of financing in the amounts and the terms necessary to support future business. You are cautioned not to place undue reliance on these forward-looking statements, which are based on the current view of management on future events and speak only as of the date of this press release. GLP does not undertake to revise forward-looking statements to reflect future events or circumstances. No assurance can be given that future events will occur, that projections will be achieved, or that GLP’s assumptions are correct.

CCTV+: From Yiwu to Jakarta: The “China Model” of the Stationery Industry Goes Global

BEIJING, Jan. 14, 2026 /PRNewswire/ — Going global has been the top concern for Yiwu merchants in recent years. Huang Changchao, President of Yiwu Stationery & Cultural Products Industry Association, is among the first who pioneered overseas ventures. Three years ago, he decided to lead the association in tapping the Indonesian market after multiple inspections.

 

Leadshine Achieves Great Success at CES 2026, Entering US and European Robotics Supply Chain

LAS VEGAS, Jan. 14, 2026 /PRNewswire/ — From January 6th to 9th, 2026, Leadshine made its debut at the Consumer Electronics Show (CES 2026) in Las Vegas. As a “full-stack solution provider for humanoid robot core components,” Leadshine captured worldwide attention in the North Hall’s humanoid robot core exhibition area, showcasing its comprehensive family of core components, from the “heart” (motors) to the “skeleton” (joints) and the “fingertips” (dexterous hands). With its innovative solutions featuring high density, high responsiveness, and high integration, Leadshine’s booth quickly became the focus of attention for the global industry chain, investors, and tech media. During this event, international industry giants such as Tesla and Boston Dynamics visited for exchanges, marking a key leap for Leadshine, from being a leading player in China to becoming an integral part of the global core supply chain.

Executives of Tesla Optimus had an in-depth discussion with Dr. Li about the strategic cooperation between coreless motors and joints
Executives of Tesla Optimus had an in-depth discussion with Dr. Li about the strategic cooperation between coreless motors and joints

Three Key Achievements Highlight Global Competitiveness

1.Phenomenal Popularity: Igniting Global Attention from Professionals to International Media

Leadshine booth attracted tens of thousands of professional visitors and industry partners from around the world, while authoritative international tech media such as CES official channels and CISION provided extensive coverage. The dynamic demonstration area for dexterous hands remained exceptionally popular, allowing visitors to experience its anthropomorphic movement and precise grasping capabilities, showcasing Leadshine’s global influence in the actuator field.

2.Robust Product Strength: Dexterous Hands and Frameless Motors Win Global Customer Favor

Dexterous Hands: With their high precision, high flexibility, and highly integrated design, the dexterous hands were pre-ordered by customers in North America, Europe, and Asia on the first day of the exhibition, highlighting the high recognition of Leadshine products in the international market.

Frameless Motors and Joint Modules: Leveraging leading power density and dynamic performance, these products are not only suitable for humanoid and quadruped robots but have also attracted customers in the fields of electric-assist bicycles, exoskeletons, and high-end medical equipment to discuss cooperation, propelling the technology into the global high-growth market.

3.Top-tier Collaboration Launched: Co-shaping the Future with Global Tech Giants‌

Executives from Tesla, Boston Dynamics, Amazon, Neura (Germany), and other companies visited the booth, engaging in multiple rounds of strategic discussions on core components for humanoid robots. Leadshine’s coreless motors, high-dynamic frameless motors, dexterous hands, and integrated joint modules received high praise. Several companies expressed clear intentions to collaborate on joint R&D and customized supply, marking Leadshine’s official entry into the core collaborative ecosystem of the global robotics industry.

Looking Ahead: Collaborating with Global Partners to Shape the Future of Robotics

This participation at CES was not only a demonstration of technological strengths but also a key milestone in Leadshine’s globalization journey. Moving forward, we will continue to deepen our expertise in motion control technology, providing the global robotics industry with more efficient and reliable “hearts, bones, and fingertips”, and jointly usher in the new era of intelligent robotics.

Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer

HONG KONG, Jan. 14, 2026 /PRNewswire/ — Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), comparing cadonilimab plus chemotherapy against a PD-1 inhibitor plus chemotherapy for the first-line (1L) treatment for advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS <5 (a propensity-matched, retrospective cohort study).

The study results showed that the cadonilimab regimen, compared to the PD-1 monoclonal antibody regimen, significantly prolonged patients’ overall survival (OS) and progression-free survival (PFS). Both OS (HR=0.49, P=0.025) and PFS (HR=0.43, P=0.006) demonstrated statistically significant improvements. The full study has been accepted for publication in the Journal of Gastrointestinal Oncology.

These real-world findings are highly consistent with the “all-comer benefit” profile previously observed for cadonilimab in the Phase III registrational trial COMPASSION-15. This real-world, head-to-head comparison further underscores cadonilimab’s potential to elevate the standard of cancer immunotherapy and address clinical challenges unresolved by single-target PD-1 inhibitors. Based on the data from the pivotal Phase III COMPASSION-15 study, cadonilimab received approval in China in September 2024 for the first-line treatment of advanced gastric cancer across all patient subgroups and this indication was added to cadonilimab’s list of covered indication under National Reimbursement Drug List (NRDL), effective 2026.

Anti-PD-1 antibodies combined with chemotherapy is the international standard of care for advanced gastric cancer. However, its efficacy is significantly limited in patients with PD-L1-low (CPS < 5) or negative (CPS < 1) expression, where these patients constitute nearly half of all advanced gastric cancer cases. As a result, the U.S. Food and Drug Administration (FDA) restricted all approved first-line PD-1 inhibitors for advanced gastric cancer to only PD-L1-positive patients in 2024. This aligns with recommendations from leading guidelines, such as those of the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO), which prioritize PD-1-based regimens for patients with PD-L1 CPS ≥5. Consequently, PD-L1-low or -negative advanced gastric cancer remains a major unmet clinical need globally due to thelack of effective immunotherapy options. A recent real-world study provides new evidence addressing this challenge.

In this retrospective analysis, patients with PD-L1-low (CPS < 5) advanced G/GEJ cancer received first-line therapy with either cadonilimab plus chemotherapy or a PD-1 inhibitor plus chemotherapy. With a median follow-up of 11.0 months as of February 28, 2025, the results showed that the cadonilimab-based regimen achieved statistically significant and clinically meaningful improvements in both PFS and OS compared to the PD-1 inhibitor-based regimen.

Some Key Findings from the Study published at GI-ASCO:

  • Significant PFS and OS Improvement: Among PD-L1-low patients, the cadonilimab group achieved a median OS of 14.3 months, significantly longer than the 10.3 months observed in the PD-1 inhibitor group (OS HR=0.49, p=0.025), representing a 51% reduction in the risk of death. The median PFS was also extended to 9.3 months compared to 5.8 months in the control group (PFS HR=0.43, p=0.006), corresponding to a 57% reduction in the risk of disease progression or death.
  • Higher Objective Response Rate (ORR): The objective response rate was superior in the cadonilimab group compared to the PD-1 inhibitor group (73.3% vs. 57.1%) for PD-L1-low patients.
  • Manageable Safety and Good Tolerability: The incidence of any-grade adverse events was comparable between the two groups, and no statistically significant difference observed in the rate of grade 3-4 adverse events between the two groups.

Akeso is actively advancing several prospective head-to-head Phase III registration studies with cadonilimab, aiming to elevate current standard immunotherapies. Notably, the international multi-center Phase III registration study COMPASSION-37, evaluating cadonilimab plus chemotherapy versus the PD-1 inhibitor nivolumab plus chemotherapy for first-line treatment of advanced gastric cancer, received approval from the U.S. FDA to initiate at the end of 2025. This milestone marks a new phase in the global development of cadonilimab.

Forward-Looking Statement of Akeso, Inc.
This announcement by Akeso, Inc. (9926.HK, “Akeso”) contains “forward-looking statements”. These statements reflect the current beliefs and expectations of Akeso’s management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso’s other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world’s first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 26 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin.

Enhanced Genetype colorectal cancer risk test released – supports earlier disease detection and ColoSTAT® targeting

MELBOURNE, Australia, Jan. 14, 2026 /PRNewswire/ — Rhythm Biosciences Ltd (‘RHY‘, the ‘Company‘ or the ‘Group‘) (ASX: RHY), a transformative, predictive cancer diagnostics technology company is pleased to announce the commercial launch of its updated geneTypeTM Colorectal Cancer (CRC) Risk Assessment clinical test (“geneTypeTM CRC”), a significant advancement in personalised cancer risk prediction. The updated test incorporates additional clinical and lifestyle risk factors alongside the established 140-SNP polygenic risk score (PRS), delivering improved predictive accuracy across both genders and a wider age range.

The enhanced test is designed to support earlier identification of individuals at elevated risk of colorectal cancer, enabling more targeted screening pathways and complementing Rhythm’s ColoSTAT® blood-based CRC detection test.

Validation data for the updated model has been recently published in the peer-reviewed journal PLOS ONE (Dite GS, et al. 2025), demonstrating improved predictive performance compared to traditional approaches.

Evidence suggests that approximately 50% of colorectal cancer cases could be prevented through healthy lifestyle modifications. By incorporating lifestyle risk factors known to contribute to disease risk, the enhanced geneTypeTM CRC test aims to identify a broader cohort of at-risk individuals who may benefit from earlier intervention and monitoring.

Key Clinical Applications

The enhanced geneTypeTM CRC Risk Assessment test has several important use-cases for this innovative new clinical test:

  1. Improved risk stratification across both genders, with particular benefits for identifying higher-risk women.
  2. Identification of younger adults at risk of early-onset colorectal cancer, supporting earlier screening interventions.
  3. Potential to encourage greater participation in bowel cancer screening programs by providing personalised risk insights.

In Australia, compliance with recommended bowel cancer screening programs remains below 50%. Individuals classified as higher risk using the geneTypeTM CRC test may be candidates for closer clinical monitoring through colonoscopy, FIT testing, or Rhythm’s blood-based CRC detection test, ColoSTAT®. “The enhanced geneTypeTM CRC test strengthens our ability to identify individuals at elevated risk earlier, supporting more targeted screening and complementing ColoSTAT’s® role in colorectal cancer detection.” said Dr Erika Spaeth, Director of Clinical Affairs at Rhythm.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives. Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions. The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

Bambu Lab Launches H2C 3D Printer, Setting a New Benchmark for Multi-Material High-Speed Printing

TOKYO, Jan. 14, 2026 /PRNewswire/ — Bambu Lab, a global leader in high-performance 3D printing, has officially introduced the H2C, a new flagship desktop 3D printer designed to bring fast, precise, and reliable multi-material printing to professional and creative users.

BambuLab H2C 3D Printer
BambuLab H2C 3D Printer

The H2C debuts Bambu Lab’s innovative Vortek Multi-Material System, which integrates high-speed printing, engineering-grade accuracy, and seamless material switching into a compact desktop platform. Unlike traditional single nozzle multi-material units. The Vortek Hotend Change system enables the use of up to six interchangeable, contactless connected hotends. Tool changes take only a few seconds, with virtually no user involvement.

Vortek Hotend Change System
Vortek Hotend Change System

Thanks to the Vortek system, the H2C can print with up to seven colors or materials in a single job, without purge-cleaning of the nozzles. Each of the six hotends can be assigned to a specific filament.

Performance is a key strength of the H2C. The printer supports print speeds of up to 600 mm/s and acceleration up to 20,000 mm/s², continuing Bambu Lab’s reputation for high-speed innovation. Combined with a fully enclosed, actively temperature-controlled chamber and intelligent airflow management, the H2C maintains dimensional accuracy and surface quality even at high speeds. From functional prototypes and industrial fixtures to creative and educational models, users can complete high-quality prints in significantly less time.

The H2C is also designed to deliver a more accessible and user-friendly experience. Automatic calibration, intelligent vibration compensation, and cloud-based slicing and job management reduce setup complexity and lower the learning curve for new users. Despite its advanced capabilities, the printer’s footprint is compact compared to previous industrial multi-material solutions, making it well-suited for laboratories, classrooms, design studios, and small workspaces.

According to Bambu Lab, the H2C represents a shift in how multi-material 3D printing is approached. Rather than adding complexity, the system focuses on making advanced capabilities work seamlessly in the background, allowing users to concentrate on design and creativity instead of operation.

With the launch of the H2C, Bambu Lab continues its mission to make high-performance 3D printing faster, more reliable, and easier to use. The new printer empowers engineers, designers, makers, and educators to explore multi-material applications with greater confidence and efficiency.

About Bambu Lab
Bambu Lab is committed to lowering the barriers to high-performance 3D printing through innovation. Known for speed, precision, and intelligent user experience, its products are used by creators and professionals in over 100 countries worldwide.

Discover Asia’s Winter Magic: Agoda Recommends Snowy Escapes for 2026

SINGAPORE, Jan. 14, 2026 /PRNewswire/ — As the 2026 winter season unfolds, digital travel platform Agoda spotlights Asia’s top snow destinations, offering travelers unparalleled experiences in some of the region’s most captivating winter wonderlands. The allure of snow-filled landscapes continues to captivate travelers, with many eager to explore the unique cultural and natural offerings of Asia’s premier snowy retreats.

With a focus on delivering memorable winter experiences, Agoda presents a curated list of top snow destinations that promise exceptional snowfall and cultural exploration:

Niseko, Japan- Niseko is celebrated for its abundant and fluffy powder snow, drawing visitors from around the globe to experience its winter magic. Beyond the slopes, Niseko offers a vibrant cultural scene, with local festivals and culinary delights that provide a taste of Japanese winter traditions. The serene beauty of snow-covered landscapes makes Niseko a must-visit for those seeking a true winter escape.

Gulmarg, India- Gulmarg, located in the picturesque region of Kashmir, offers a breathtaking winter experience with its deep snow and panoramic views of the Himalayas. The region’s rich cultural tapestry and historic sites provide a fascinating backdrop to the winter wonderland. Travelers can immerse themselves in the local culture, enjoying the warmth of Kashmiri hospitality amidst the snow.

Pyeongchang, South Korea- Pyeongchang is renowned for its winter beauty and cultural richness. Visitors can explore the Odaesan National Park, which transforms into a serene snow-covered wonderland during winter. The area is also home to the Woljeongsa Temple, where travelers can experience traditional Korean temples stay amidst the tranquil snowy landscape. Pyeongchang’s local markets offer a taste of regional delicacies, making it a perfect destination for those seeking cultural immersion.

Almaty, Kazakhstan- Almaty offers a captivating winter experience with its stunning natural scenery and vibrant cultural scene. The city is surrounded by the majestic Tian Shan mountains, providing breathtaking views and opportunities for winter hiking and exploration. Visitors can enjoy the local culture by exploring Almaty’s museums, theaters, and bustling markets, where traditional Kazakh crafts and cuisine are showcased. The city’s unique blend of natural beauty and cultural heritage makes it an ideal winter destination.

Jay Lee, Regional Director, North Asia at Agoda, shared, “Asia’s snow destinations offer a perfect blend of natural beauty and cultural richness. Whether you’re marveling at the snow in Niseko or exploring the majestic Himalayas in Gulmarg, these locations provide unforgettable experiences. Agoda is thrilled to connect travelers with these incredible destinations, offering great deals on flights, accommodations, and activities.”

For those planning their winter getaways, Agoda offers over 6 million holiday properties, more than 130,000 flight routes, and over 300,000 activities, all of which can be combined in the same booking. Discover the best deals on Agoda’s mobile app and start planning your next adventure today.

/U P D A T E — Kat Florence/

In the news release, Kat Florence Hotel Unveils Daily La Mer Massages Included, Michelin-Origin ‘Infinity Pâtisserie,’ and a Nordic Winter Spa, issued Jan. 14, 2026 by Kat Florence over PR Newswire, we are advised by the company that changes have been made. The complete, updated release follows:

Kat Florence Hotel Unveils Daily La Mer Massages Included, Michelin-Origin ‘Infinity Pâtisserie,’ and a Nordic Winter Spa

The world-renowned luxury jeweller brings her signature precision and taste to a new era of bespoke “all-inclusive” where ultra-luxury amenities are included essentials in every stay

ELORA, ON, Jan. 14, 2026 /PRNewswire/ — The Kat Florence Hotel, restored and designed by seven-time world record–breaking rare gem jeweller Kat Florence, announces an expanded collection of ultra luxury, inclusive experience layers arriving this month. 

Photo by George Pimentel.
Photo by George Pimentel.

Kat Florence, who grew up in Canada’s famously beautiful village of Elora where her retreat resides, invested millions to personally restore the historic 1848 limestone building to its immaculate, present-day aura. “I approach a space the same way I approach a rare gemstone,” says Florence. “Its history and composition tell you what it wants to become. My role is to honour that story and elevate it. Our elaborate guest gifts and amenities also directly reflect the space, as well as our ethos of being a true home away from home. We’re thrilled to launch the next chapter of the hotel with even more signature, always included layers of wellness, nature, Michelin-level nourishment, and the most luxurious self-care elixir on earth (La Mer).”

Officially launching this month, the hotel debuts its private, guest-only Nordic Wellness Spa, a secluded plein air sanctuary within its hidden outdoor space. Steps from each suite, this intimate wellness garden features a hand-crafted cedar sauna, open-air hot pool, a restorative cold-plunge circuit for contrast therapy and a firepit lounge area; all supported by discreet, on-demand drink and snack service. Elemental, calming, and meticulously scaled, the spa is a sensorial extension of Florence’s design philosophy: purity, balance, and craftsmanship at every turn.

To further complement their already much loved, daily 60 minute full-body massages for all staying guests, delivered in the privacy of their suite by expert in-house RMTs, Kat’s daily ritual will soon be incorporating her personal favourite self-care product. From January, massages will be enhanced with a La Mer the renewal oil–infused face, neck, and décolleté finishing ritual (the La Mer elixir which famously retails for $395 per mini 30ml ounce bottle). The treatment also incorporates sound bath therapy and the Nordic practice of steam and ice, alternating warm and cool towel compresses to awaken the senses and create a harmony of temperature, grounding guests in the moment.

Adding to the hotel’s sensory and wellness offerings, December 18 also marks the debut of the Kat Florence Hotel’s new infinity-style Patisserie, a private, guest-only experience of daily edible art creations led by Chef Marc Collyer. The bakes and bonbons collection will be crafted using the most expensive ingredients on earth. While the collection will change every day, guests can expect delights like ‘mille feuille of housemade caramelized puff pastry, green apple caviar and hazelnut creme,’ ‘Caramelized white chocolate eclair with Amarena cherry mousse and burnt orange & Champagne powder,’ and signature house croissants Chef ferments for 3 full days prior to baking resulting in magnificently deepened flavours. Prior to collaborating with Kat, Marc spent 14 years honing his culinary distinction and imaginative flair at twice Michelin-starred Manor House in the British Cotswolds. Now innovating fine dolce delights at the Elora retreat, his guests are encouraged to visit in limitless tasting fashion throughout their stays (all at no charge; Chef’s high design cakes, chocolates and pastries are included for guests). In addition, each morning Chef Marc hand-churns his own butter and fresh bakes pastries, breads and more, sending energizing creations to be personal concierge-delivered to each suite as part of the hotel’s bespoke breakfast service. His patisserie program now forms an essential pillar of the property’s culinary identity, blending technique, artistry, and an intimate, at-your-leisure approach to Michelin heights indulgence.

Reflecting Florence’s celebrated eye for rarity and refinement, the hotel remains intentionally exclusive, welcoming a maximum of only 14 guests at any time and offering an unprecedented 2:1 staff-to-guest ratio; one of the highest in North America versus a luxury hotel average of 10:1. The result is a sanctuary of calm and privacy, with made-to-measure service for every stay.

Every booking at the Kat Florence Hotel includes her famous roster of signature high end gifts, services and experiences, all crafted to feel effortless and personal:

  • Daily, 60-minute full body massages in-suite including La Mer the renewal oil infused face, neck and decolletage ritual (Kat’s personal favourite self-care ritual)
  • A multi-course Chef’s Tasting Dinner on guests’ arrival night, prepared and hosted by renowned Chef Anthony Bish in his Anthony’s Private Restaurant reserved exclusively for hotel guests.
  • Suite-delivered Breakfast Baskets every morning with daily rotating pastries, breads, hand-churned butter and more presented by Chef Marc Collyer (formerly of twice Michelin-starred Manor House in the British Cotswolds)
  • A full bottle of Veuve Clicquot Champagne awaiting each guest upon arrival
  • Rolls Royce & Bentley chauffeur service around town as well as complimentary valet
  • Dedicated, personal concierge throughout your stay available for any request — from unpacking to private shopping to meal delivery to laundry service
  • Enjoyment of the new ultra-private outdoor Nordic Spa just steps from the suites in the garden including hand-crafted cedar sauna, hot-pool therapy, cold-pool circuit and on-demand drink service
  • Infinity visits to Kat Florence Hotel’s private, guest-only Patisserie day to night to experience Chef Marc’s daily edible art creations in unlimited fashion (at no cost)

The brand philosophy is one of complete ease with every detail anticipated, every moment curated.

To reserve or learn more, explore at www.katflorencehotels.com or at @katflorencehotels on Instagram. For more information on Kat Florence’s seven-time world record-breaking, ultra rare gem jewellery which all entirely one-of-a-kind pieces, visit www.katflorence.com or @katflorence on Instagram.

Media contact: Jessica Rodrigues, Email: Rodriguesjess@gmail.com